Clinically Media at ASCP 2026: Advancing Neuropsychiatric Clinical Trials with LyfeSci
Clinically Media is excited to attend the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29, 2026, in Miami Beach, Florida.
The ASCP Annual Meeting is widely regarded as one of the premier gatherings in psychopharmacology and neuropsychiatric drug development, bringing together leaders from academia, industry, and government. Researchers from organizations such as the NIH, FDA, and international regulatory agencies join biotech companies and pharmaceutical sponsors to discuss emerging science, clinical trial innovation, and the evolving future of psychiatric therapeutics.
This year’s theme—“Psychiatry and AI: Promises, Perils, and Pathways Forward”—highlights the growing intersection of neuroscience, artificial intelligence, and personalized medicine in the development of treatments for neuropsychiatric conditions.
For Clinically Media and LyfeSci, ASCP provides an important opportunity to connect with organizations advancing research across the central nervous system (CNS) landscape.
Expanded CNS Capabilities Through LyfeSci
This year’s ASCP meeting is particularly meaningful following the recent acquisition of Clinically Media by LyfeSci Research & Innovation.
Earlier this year, LyfeSci expanded its clinical development capabilities by bringing Clinically Media into the organization to strengthen patient recruitment and patient-centric clinical trial capabilities. The acquisition allows both teams to provide more integrated support for sponsors running complex CNS and neuropsychiatric studies.
You can read the full announcement here:
LyfeSci Research & Innovation Acquires Clinically Media
LyfeSci’s CEO and Founder, Tapan Parikh, MD, MPH, MBA, will also be participating in the meeting.
As a psychiatrist and clinical research leader, Dr. Parikh brings deep expertise in neuropsychiatric drug development and early-stage biotech strategy. His experience supporting companies as they move innovative therapies from early scientific discovery into clinical testing positions LyfeSci as a valuable partner for organizations developing new CNS treatments.
Together, LyfeSci and Clinically Media provide sponsors with support that spans early development strategy, clinical operations, and patient recruitment.
Experience Supporting CNS Clinical Trials
Clinically Media has extensive experience supporting recruitment for CNS and neurological clinical trials. Our team has developed targeted strategies to reach patients living with complex neurological and neuropsychiatric conditions, helping sponsors and research sites meet enrollment goals while maintaining a strong patient-first approach.
You can explore more about our therapeutic expertise in CNS clinical trial recruitment on our website.
Recent examples of our work include:
Alzheimer’s Disease Clinical Trial Recruitment
Clinically Media has supported enrollment efforts for studies evaluating potential treatments for Alzheimer’s disease, developing recruitment strategies designed to reach both patients and caregivers.
Read the case study:
Supporting Alzheimer’s Enrollment Efforts for Potential Treatments
Migraine Clinical Trial Recruitment
Our team has also supported recruitment for studies focused on migraine, helping research teams connect with patients experiencing chronic and episodic migraine conditions.
Read the case study:
Supporting Migraine Enrollment Efforts for Potential Treatments
Early-Stage Parkinson’s Disease Research
Clinically Media also supported recruitment efforts for the Neuraly PRISM study, focused on patients with early-stage Parkinson’s disease. The project required specialized outreach strategies to reach appropriate patient populations and support study enrollment.
Read the case study:
Neuraly PRISM Study: Early-Stage Parkinson’s Disease
Connecting with the Neuropsychiatric Research Community
The ASCP Annual Meeting is an important forum for advancing conversations about the future of psychiatric therapeutics, neurobiology, and clinical trial innovation.
Clinically Media and LyfeSci are particularly excited to connect with:
Biotech companies developing novel neuropsychiatric therapies
Sponsors preparing early-stage CNS clinical trials
Organizations exploring biomarkers, AI-driven research, and personalized medicine approaches
Research teams seeking strategic support for patient recruitment and trial execution
Let’s Connect at ASCP
If you will be attending the ASCP Annual Meeting in Miami Beach, we would love to connect.
Our teams look forward to meeting organizations working across the CNS landscape and discussing how the combined expertise of LyfeSci and Clinically Media can help accelerate neuropsychiatric clinical development… from early scientific strategy to patient recruitment and trial execution.
We look forward to the conversations that will help move neuropsychiatric research and treatment innovation forward.
